All In Biotech

NDA 206940 · Abbvie

Viberzi

Eluxadoline · Oral · mu-Opioid Receptor Agonist

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jun 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

May 27, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 1 recruiting

FAERS reports

2,949

1,137 serious, 69 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 16, 2024.

VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). VIBERZI is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). ( 1 )

Mechanism: Eluxadoline is a mu-opioid receptor agonist; eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist. The binding affinities (Ki) of eluxadoline for the human mu and delta opioid receptors are 1.8 nM and 430 nM, respectively. The binding affinity (Ki) of eluxadoline for the human kappa opioid receptor has not been determined; however, the Ki for guinea pig cerebellum kappa opioid receptor is 55 nM. In animals, eluxadoline interacts with opioid receptors in the gut.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VIBERZI · ELUXADOLINE 100MG · TABLET, ORAL · Prescription · TE AB
  • VIBERZI · ELUXADOLINE 75MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Eluxadoline" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use364
  • abdominal pain352
  • diarrhoea348
  • constipation283
  • pancreatitis278
  • nausea220
  • drug ineffective218
  • abdominal pain upper210
  • inappropriate schedule of drug administration162
  • vomiting137
  • fatigue118
  • dizziness108

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20153
2016837
2017724
2018266
2019318
2020184
2021116
202295
2023116
202492
2025120
202677

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Viberzi (Eluxadoline)

2024 spending

$59.2M

Beneficiaries

6,935

34,827 claims

Per beneficiary

$8,539

$26.18 per unit

View as table
YearSpending
2020$60,194,815
2021$58,110,619
2022$59,159,196
2023$59,717,509
2024$59,221,425

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.